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Background: Endothelial progenitor cells (EPCs) can be used to treat ischemic disease
in cell-based therapy owing to their neovascularization potential. Glucocorticoids (GCs)
have been widely used as strong anti-inflammatory reagents. However, despite their
beneficial effects, side effects, such as impairing wound healing are commonly reported
with GC-based therapy, and the effects of GC therapy on the wound healing function of
EPCs are unclear.
Methods: In this study, we investigated how GC treatment affects the characteristics
and wound healing function of EPCs.
Results: We found that GC treatment reduced the proliferative ability of EPCs.
In addition, the expression of CXCR4 was dramatically impaired, which suppressed
the migration of EPCs. A transplantation study in a flap mouse model revealed that
GC-treated EPCs showed a poor homing ability to injured sites and a low activity for
recruiting inflammatory cells, which led to wound healing dysfunction. Impairment of
prostaglandin E2 (PGE2) synthases, cyclooxygenase (COX2) and microsomal PGE2
synthase 1 (mPEGS1) were identified as being involved in the GC-induced impairment
of the CXCR4 expression in EPCs. Treatment with PGE2 rescued the expression of
CXCR4 and restored the migration ability of GC-treated EPCs. In addition, the PGE2
signal that activated the PI3K/AKT pathway was identified to be involved in the regulation
of CXCR4 in EPCs under the effects of GCs. In addition, similar negative effects of
GCs were observed in EPCs under hypoxic conditions. Under hypoxic conditions,
GCs independently impaired the PGE2 and HIF2α pathways, which downregulated the
expression of CXCR4 in EPCs. Our findings highlighted the influences of GCs on the
characteristics and functions of EPCs, suggesting that the use of EPCs for autologous
cell transplantation in patients who have used GCs for a long time should be considered
carefully.
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INTRODUCTION
Glucocorticoids (GCs) have been widely used as extremely
effective agents for suppressing inflammation associated with
various kinds of diseases (1). However, despite its beneficial
effects, GC treatment is associated with several deleterious effects,
including impaired wound healing (2). This side effect happens
either via the transrepression of pro-inflammatory cytokines,
growth factors, matrix proteins and matrix protease or via
direct inhibitory influence on genes that are important for skin
regeneration (3). GCs act as the synthetic analogs of human
natural endogenous GCs, which exert their effects by binding to
GC receptors (GRs), thereby regulating the expression of target
genes that play important roles in the wound healing process
(4). In addition, GCs also cause the dysfunction of cells involved
in wound healing (5, 6). We recently demonstrated that GC
treatment impairs the wound healing function of adipose tissue-
derived mesenchymal stem cells (MSCs) via the downregulation
of stromal cell-derived factor 1 (SDF-1) (5).
Wound healing is a complex process that requires the
contribution of many cell types (7). Central to this, MSCs
and endothelial progenitor cells (EPCs) play crucial roles in
promoting wound healing (7). While MSCs contributes to the
wound healing process mostly via paracrine effects, secreting
a mixture of growth factors and vesicles to recruit numerous
of cells to the wound sites and support these cells’ functions,
EPCs are the key effectors of neovascularization and are involved
in the formation of blood vessels and maintenance of the
function of the vascular endothelium (8). EPCs possess the self-
renewal potential, differentiation ability to endothelial cells, and
neovascularization capability toward new blood vessel formation
(9, 10). A previous study showed that EPCs accelerate wound
healing not only as the endothelial substrate of blood vessels but
also by migrating to the injured tissue, exerting their effects by
excreting proangiogenic factors (10).
The definition of an EPC has been controversial. Originally,
EPCs were identified as the cell population isolated from human
peripheral blood that expresses the CD34 and Flk1 markers (11).
However, recently studies have highlighted that positive with
CD34 and Flk1 are insufficient to define EPCs in vitro (8). Several
studies have reported the two distinct types of EPCs, early and
late EPCs, which early EPCs are characterized by the expression
of CD45 and CD14, together with some endothelial cell (EC)
markers, and have a short lifespan of 3–4 weeks. Additionally,
late EPCs are characterized by EC markers, such as CD31, CD34,
VEGFR2, and VE-cadherin, but are negative for myeloid markers
(12). We previously reported a novel method for isolating EPCs
according to the aldehyde dehydrogenase (ALDH) activity which
showed that the expression of CD34 declines during the culturing
of DiI-Ac-LDL–positive/CD45−/CD31+ cells; whereas, ALDH
activity was retained stably in EPCs in long term culture (13).
Of note, EPCs with a low ALDH activity (Alde-low) possess
a higher migratory ability toward damaged tissue and show a
better recover ability in ischemic wound healing than Alde-high
EPCs (13). Under hypoxic conditions, Alde-low EPCs are highly
responsive and show the upregulation of hypoxic condition
inducible factor 2α (HIF2α), which regulates the expression
of CXCR4, a major chemokine receptor for cell migration
in response to SDF-1 (13). Therefore, Alde-low EPCs can be
considered promising candidates for wound treatment (13).
Autologous transplantation of EPCs is considered a
prospective approach for therapeutic revascularization and
chronic wound (14). It is reported that autoimmune diseases
and its drug-based therapy, such as GC, account for 20% of
chronic wound cases (15). Therefore, the patients who have been
receiving GC treatment are one of the major targets for EPC
therapy. However, similar to other cell sources, the introduction
of autologous EPCs transplantation into clinical treatment is
still being met with difficulty due to the negative influence of
patients’ medical backgrounds on the outcome of the treatment
(16, 17). Ensuring the EPCs’ potential is crucial for achieving the
best outcome of EPC-based therapy. A previous study suggested
that chronic GC treatment reduces the number of circulating
EPCs in the patients (16). However, no report has yet clarified
the influences of GCs on the wound healing ability of EPCs.
Thus, whether or not the outcomes of EPC-based therapy are
worsened in patients who have been chronically treated by GCs
remains unclear.
In the present study we examined whether or not GCs
interfere with the wound healing ability of Alde-low EPCs.
We found that GCs downregulated the expression of CXCR4
in a transplantation flap mouse model, which impaired the
migration and wound healing ability of EPCs. Treatment with
PGE2 upregulated the EP4 receptor and activated the PI3K/AKT
signaling which were involved in rescuing the detrimental
effects of GC on the CXCR4 expression of EPCs. In addition,
similar detrimental effects of GCs on the PGE2/CXCR4 pathway
were noted in EPCs under hypoxic conditions. Of note, under
hypoxic conditions, independent with the PEG2 pathway, the
HIF2α pathway was also involved in the GC-impaired CXCR4
expression in EPCs. Taken together, these findings highlight the
negative effects of GCs on the EPC functions, suggesting that
autologous EPC therapy for patients receiving GC treatment be
considered carefully.
MATERIALS AND METHODS
Isolation of Umbilical Cord Blood-Derived
EPCs
All experiments involving human subjects were performed in
accordance with the Guidelines for Medical and Health Research
Involving Human Subjects, Ministry of Education, Culture,
Sports, Science and Technology, Japan and the permission of
the Institutional Ethics Review Committee of the University
of Tsukuba. Human EPCs were isolated from umbilical cord
blood (UCB), as previously described (13). Isolated EPCs were
sorted based on the ALDH activity using ALDEFLUOR R©
system reagents (StemCell Technologies, Vancouver, Canada).
The EPCs with the low ALDH activity (Alde-low EPCs) were
used for further experiments in the present study. Alde-
low EPCs were cultured with maintenance medium (Iscove’s
modified Dulbecco medium-IMDM, Invitrogen, Carlsbad, CA,
USA)/10% FBS/5 ng/mL bFGF (PeproTech, NJ, USA), and 0.1%
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(v/v) penicillin-streptomycin (100 U/mL penicillin, 0.1 mg/mL
streptomycin; Invitrogen) and incubated at 37◦C in 5% CO2.
A Fluorescence Activated Cell Sorting
(FACS) Analysis of EPCs
EPCs were harvested with trypsin, counted the cell number and
a number of 2 × 105 cells were reconstituted in 100 µl 2% FBS-
containing PBS. For staining purpose, cells were incubated with
the desired antibodies for 30min at 4◦C.
The following antibodies were utilized with the volume of 5µl
as the recommendation of the manufacturer: PE-labeled anti-
CD105 (323206, BioLegend), PE-labeled anti-CD73 (550257,
BD Pharmingen), PE-labeled anti-CD31 (303106, BioLegend),
allophycocyanine (APC)–labeled anti-CD45 (555485, BD
Biosciences, San Jose, CA), and FITC-labeled anti-CD34
(555821, BD Biosciences). Purified-anti-VEGFR-2 were used as
previously reported (13). APC-labeled anti-IgG1 (555751, BD
Biosciences), PE-labeled anti-IgG1 (555749, BD Biosciences),
FITC-labeled anti-IgG1 (555748, BD Biosciences) were used as
the isotype controls. After staining, cells were washed by 2%
FBS-containing PBS, centrifuged at 1,800 RPM for 3min at 4◦C,
and reconstituted in 300 µl 2% FBS-containing PBS. A flow
cytometer (MoFlo XDP; Beckman Coulter, Pasadena, CA, USA)
collected 10,000 events for each group, and the isotype control
IGg was used as the negative control.
In order to quantify CXCR4 expression in EPCs, the cells were
stained with 5µl of PE-labeled anti-CXCR4 (306506, BioLegend)
and performed the FACS analysis with the similar above protocol.
PE-labeled anti-IgG1 (555749, BD Biosciences) was used as
the isotype controls. The threshold for CXCR4-positivity was
quantified bymeans of fluorescent intensity value subtracted with
isotype control value IgG of each group.
Cell Proliferation Assay
The proliferation of EPCs was evaluated by the growth curve and
proliferation assay staining with Cell Counting Kit-8 (CCK-8,
Dojindo, Tokyo, Japan).
For growth curve, EPCs were seeded at a number of 4×103
cells/well in the 24 well-plate dishes and cultured at 37◦C in
5% CO2 for 9 days. The culture medium was changed every 3
days. The cells were washed with sterile PBS and treated with
0.05% trypsin/EDTA (Invitrogen) at 24-h intervals for 9 days to
separate single cells. Dead cells were excluded using trypan-blue
staining solution (35525-02; Nacalai Tesque, Kyoto, Japan), and
the numbers of live cells in triplicate dishes were counted using a
hemocytometer.
For proliferation assay staining with CCK-8, EPCs were
seeded at a number of 2.5 × 104, 1.25 × 104, and 6.25 × 103
cells/well in 96-well microplate. Cells were incubated for 48 h and
10 µl of Cell Counting Kit-8 reagent was added to each well,
then incubate for 2 h. The number of live cells were measured
by colorimetric reading using a microplate reader (Varioskan,
ThermoFisher Scientific, Massachusetts, USA) for 450 nm.
Annexin-V/7AAD Staining Assay
EPCs were trypsinized and centrifuged at 1,000 RPM for 3min
at 4◦C. Cells were then resuspended in 100 µl of 2% FBS and
stained with 5 µl of PE annexin V and 7-AAD (BD BioSciences
(CA, USA), and then incubated at 4◦C in the dark for 30min. FBS
(2%, 300 µl) was added, and the apoptotic cells were analyzed by
flow cytometry.
In vitro Migration Assay
Scratch assay: An in vitro migration assay was performed as
previously reported with minor modifications (18). EPCs with
a number of 1.5 × 105 cells were seeded onto 4-well plates
with maintenance medium until they reached confluency after
24 h. Scratch wounds ∼1mm wide were created. After gentle
washing of the detached cells with PBS, the growth medium was
changed to 2% FBS-containing IMDM. The pictures of wound
closure were taken every 6 h during 24-h post-scratching at
100× magnification (10× objective and 10× eyepiece) under a
microscope (Olympus, Tokyo, Japan). The cell migration was
calculated using the ImageJ software program (NIH, MD, USA).
The wound closure distance was measured at the beginning (T0)
and end of the experiment (Tx). The following formula was used
to convert the migrated area to percentage: Percentage (%) of
wound closure= T0 – TX = [1 – X/T0 × 100].
Transwell Migration Assay
A volume of 600 µl SDF-1 (100 ng/ml) in IMDM medium was
placed in the lower chamber of each well of 24 well-plates.
Afterwards, a volume of 200 µl IMDM medium containing
3 × 104 EPCs added in the upper chamber of 8µm pore
sized of filter membrane. After 24 h of incubation, the lower
side of filter was washed with PBS and fixed with 2% PFA.
The number of migrated EPCs which migrate toward SDF-
1 was determined by Hematoxylin & Eosin staining and
counted under the observation using a microscope (Olympus) at
100×magnification.
Gene Expression Analyses
Total RNA was isolated from cultured EPCs using extraction
reagent (Sepasol-RNA I Super G; Nacalai Tesque), and reverse
transcription was performed with 1 µg of the total RNA using
a reverse transcription polymerase chain reaction (RT-PCR) kit
(Toyobo, Osaka, Japan). The expression of the target genes was
analyzed using a GeneAmp PCR System (Life Technologies, CA,
USA) with Thunderbird SYBR qPCRMix (Toyobo). Experiments
were carried out in triplicate, and the expression of the target
genes was calculated using the 2−11CT method. β-Actin was used
as an internal control. The primer sequences used for quantitative
RT-PCR are shown in Table 1.
In vivo Wound Healing Model
C57BL/6 mice were purchased from Charles River Japan,
Inc. (Kanagawa, Japan). All experiments were performed
in compliance with the Fundamental Guidelines for Proper
Conduct of Animal Experiment and Related Activities in
Academic Research Institutions under the jurisdiction of the
Ministry of Education, Culture, Sports, Science and Technology,
Japan. Each experiment was repeated triplicate. In order to
compare the wound healing ability of untreated EPCs and GC-
treated EPCs, total 15 male mice at 12th week of age were used in
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TABLE 1 | The primer sets for the quantitative polymerase chain reactions.
Gene Primer Sequence
βactin Forward GTGCGTGACATTAAGGAGAAGCTGTGC
Reverse GTACTTGCGCTCAGGAGGAGCAATGAT
VEGF Forward AGATGAGCTTCCTACAGCACAAC
Reverse AGGACTTATACCGGGATTTCTTG
PDGF-AA Forward TAGGGAGTGAGGATTCTTTGGACACCA
Reverse CAAATGCTCCTCTAACCTCACCTGGAC
FGF Forward AGAGCGACCCTCACATCAAGCTACAAC
Reverse ATAGCTTTCTGCCCAGGTCCTGTTTTG
Ang-1 Forward GCCTGATCTTACACGGTGCT
Reverse GGCCACAAGCATCAAACCAC
SDF-1 Forward AGAGCCAACGTCAAGCATCT
Reverse CTTTAGCTTCGGGTCAATGC
CXCR4 Forward CCTTATCCTGCCTGGTTATTGTC
Reverse AGGATGAGGATGACTGTGGTCT
CXCR7 Forward AGAGCTCACAGTTGTTGCAAAGTGC
Reverse GGTTCAAGATGTAGCAGTGCGTGTC
CCL2 Forward GAATCACCAGCAGCAAGTGT
Reverse GTTTGGGTTTGCTTGTCCAGG
TGF-β Forward AGAGCTCCGAGAAGCGGTACCTGAACCC
Reverse GTTGATGTCCACTTGCAGTGTGTTATCC
COX-2 Forward GGCAGGAGGTCTTTGGTCT
Reverse AACTGCTCATCACCCCATTC
mPGES-1 Forward GGAACGACATGGAGACCATGTAC
Reverse TCCAGGCGACAAAAGGGTTA
EP-4 Forward CCTCAGCGACTTTCGGCG
Reverse ACGAATACTCGCACACGAG
each experiment and divided into three groups (5 mice/group):
PBS, EPCs, GC-treated EPC. In order to examine the role of
CXCR4 in the wound healing ability of EPCs, total nine male
mice at 12th week of age were used in each experiment and
divided into three groups (3 mice/group): untreated EPCs, GC-
treated EPCs, and CXCR4 antibody-treated EPCs (AMD3100,
Sigma-Aldrich). 100 nM of AMD3100 at 24-h treatment was
used to block the CXCR4. The mice were anesthetized using
avertin, and a skin incision (3 × 2 cm) was made to create
an ischemia gradient as previously described (19). EPCs were
treated with 100 nM GC for 24 h prior to surgery then labeled
with PKH26 (Sigma-Aldrich, Missouri, USA) as the instruction
of the manufacturer before transplantation. PBS and PKH26-
labeled untreated EPCs were used as the controls. The EPCs
were injected at a number of 5 × 105/mouse through the
tail vein. Skin tissue samples were fixed overnight with 4%
paraformaldehyde; then, washed with PBS, soaked in sucrose
10% for 2 h, and finally in sucrose 20% overnight. Then, the
frozen blocks of samples were made by embedded the samples in
the O.C.T compound (Sakura Finetek, Tokyo, Japan) and freeze
in liquid nitrogen. After that the tissues were sectioned before
immunostaining. For observation, the flap tissues were collected
at two different time points: on the third day of transplantation
to analyze the inflammatory cell recruitment and on the seventh
day of transplantation to analyze the neovascularization. Images
of the ischemic flaps were captured on the seventh day of
transplantation, and the necrotic areas were quantified using the
Image J software program (NIH).
Histological Analyses
The frozen flap tissue sections were mounted, stained with
hematoxylin and eosin (Wako, Osaka, Japan) and observed
under a microscope (Olympus, Tokyo Japan). The inflammatory
cells recruited in the ischemic area were visualized by
immunohistochemical staining with rat anti-mouse CD45
(553078, BD Pharmigen), rat anti-mouse Mac1 (rat anti-mouse
CD11b 550282, BD Pharmigen). The neovascularization was
analyzed by immunohistochemical staining with rat anti-mouse
CD31 (553370, BD Pharmigen) as the instruction of the
manufacturer. Briefly, sections were washed in PBS and then
rinsed in 10% H2O2 in PBS before blocking with blocking
buffer containing Phosphate-Buffered Saline with 0.5% Tween
20 (PBST) and normal rabbit serum at a dilution of 4:1 (v/v)
for 1 h at room temperature. After that, the sections were
incubated with appropriate antibody overnight. On the following
day, the sections were washed with PBST before incubating
in the secondary antibody (POD Conjugate Anti-rat, MK-
201, Takara, Shiga, Japan) for 30min at room temperature.
The sections were then washed with PBS and covered with
0.05% 3,3
′
-Diaminobenzidine (DAB) solution (Sigma-Aldrich)
in PBS with H2O2 for 3min then stopped detection by water.
Quantification of the number of positive cells was performed
at 200× magnification (20× objective and 10× eyepiece) under
a microscope (Olympus) by counting the brown dots in 10
fields.
Western Blotting
Cultured EPCs were harvested, counted and a number of 106
cells were suspended in low-salt buffer (10mM HEPES, 10mM
KCL, 1mM dithiothreitol, 1mM EDTA, protease inhibitor
cocktail (PIC), and 1% Nonidet P-40, Roche Diagnostics, Basel,
Switzerland), and nuclear pellets were collected by centrifugation.
The nuclear pellets were then suspended in high-salt buffer
(20mM HEPES, 400mM NaCl, 1mM dithiothreitol, and 1mM
EDTA, PIC), and the nuclear extract was obtained. The total
protein concentration was measured by Bradford assay (Bio-
rad, CA, USA) as the instruction of the manufacturer. 30µg
protein of each nuclear extract samples were separated on 10%
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred onto a PVDFmembrane (EMDMillipore,
Darmstadt, Germany).
An immunoblotting analysis was performed. Briefly, the
membranes were blocked with 5% Bovine Serum Albumin
(Sigma-Aldrich, Missouri, USA) in Tris-Buffered Saline with
0.5% Tween 20 (TBST) for an hour at room temperature, then
incubated incubation with the appropriate primary antibody
overnight. Primary antibodies were diluted at the dilution of
1:1,000 (v/v) as the instruction of the manufacturer, including:
Rabbit anti-human AKT (9272S, Cell Signaling Technology,
Massachusetts, USA, phosphorylated AKT antibody (9271S,
Cell Signaling Technology), rabbit anti-human HIF-2α antibody
(NB100-122, Novus Biologicals, CO, USA), and goat anti-Lamin
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B antibody (M-20, Santa Cruz Biotechnology, Inc., CA, USA.
The membranes were washed with TBST buffer then incubated
with secondary antibodies, including: Horseradish peroxidase
(HRP)-conjugated goat anti-rabbit IgG (32460, ThermoFisher
Scientific) and rabbit anti-goat IgG (31402, ThermoFisher
Scientific) with the dilution of 1:10,000 (v/v) for an hour at
room temperature. Then, the membranes were washed and the
enhanced chemiluminescence (GEHealthcare, Illinois, USA) was
used for detection by a luminescent image analyzer (ImageQuant
LAS4000, GE Healthcare). The band densities of target proteins
were analyzed by ImageJ software (NIH). The relative expressions
of target proteins were normalized with the total-LaminB
expression. For the phosphorylation analysis, after incubation
with phosphorylated antibody and detected the phosphorylated
protein, the membranes were striped with Restore Stripping
Buffer (ThermoFisher Scientific) for 15min at room temperature,
then, continued to incubate with rabbit Akt antibody. The Akt
signals were detected and the membranes were then stripped and
re-probed with LaminB antibody.
Statistical Analyses
Data were statistically analyzed usingMannWhitney U test using
the GraphPad Prism 5 software program (GraphPad Software,
CA, USA) as appropriate. Data are presented as the mean ±
standard deviation. P < 0.05 was considered as significant.
RESULTS
GC Treatment Impaired the Proliferation
Ability of EPCs
A previous report stated that GCs induced apoptosis in
lymphocytes, demonstrating the negative effects of GCs on cells
(20). However, thus far, no report has described the effects of
GCs on EPCs; therefore, in the present study, we examined the
characteristics of EPCs, including the cell morphology, viability,
surface markers, and proliferation, under treatment with 100 nM
dexamethasone as a GC. We found that GC treatment exerted
no effects on the adherence or visual appearance of EPCs
(Figure 1A). In addition, Annexin-V/7AAD staining assay data
showed that 24-h treatment of GC showed no apoptosis
induction or any cytotoxicity in EPCs (Figure 1B).
To examine the effects of GC on the EPC surface markers, a
FACS analysis was performed. The data showed that there were
no significant changes in the self-surface markers of EPCs under
GC treatment, with both control and treated groups expressing
high levels of CD31, CD34, CD105, CD73, and VEGFR2 and not
expressing CD45 hematopoietic marker at all (Figure 1C). Next,
we investigated the effects of GC treatment on the proliferation
ability of EPCs. The data showed that the proliferation ability of
EPCs treated with GCwas significantly impaired compared to the
untreated EPCs (Figures 1D,E). Taken together, these data show
that GC impaired the proliferation ability of EPCs.
GC Impaired the in vitroMigration Ability of
EPCs via the Downregulation of CXCR4
Previous studies have described the negative effects of GCs on the
wound healing process (3, 20). Recently, we also reported that
GCs impair the wound healing function of mesenchymal stem
cell by reducing the expression of SDF-1 (5). Therefore, in the
present study, we thought that GCs might also affect the wound
healing function of EPCs. To test this hypothesis, we evaluated
the wound healing function of EPCs under GC treatment.
First, because the EPC migration ability is critical for their
biological properties, the effect of GC on the migration ability
of EPCs was evaluated by a scratch assay as an in vitro wound
healing model (21). As shown in Figure 2A, GC-treated EPCs
showed a lower capability of wound closure than the control,
indicating a reducedmigration ability of EPCs on exposure to GC
(Figures 2A,B).
Next, we assessed the expression profiles of the wound
healing-related genes in EPCs. Numerous reports have shown
that EPCs express multiple chemokines and their receptors
related to mobilization (SDF-1, CXCR4, CXCR7), angiogenesis
(Ang-1, TGFβ), immunomodulatory (CCL2), and growth factors
(PDGF, VEGF, FGF) that play a critical role in wound healing
(22, 23). To clarify how GC interferes with the wound healing
capacity of EPCs, we examined the mRNA expression of those
genes in GC-treated EPCs.
We observed a significantly impaired expression of CXCR4,
which related to the mobility (24) and CCL2, which related to
the inflammatory cell recruitment (25, 26) in GC-treated EPCs
compared to that in control cells (Figure 2C). In addition, several
genes that contribute to EPC migration, such as the extracellular
matrix (ECM) protease MMP9 and homing and adherence factor
VCAM 1, were also downregulated due to GC treatment (data
not shown). Consistent with themRNA expression data, a further
FACS analysis showed a reduction in the CXCR4 surface protein
level (Figure 2D).
It is reported that the SDF-1/CXCR4 cascade is responsible
for the mobilization of EPCs (10). Therefore, we next
performed the transwell assay to examine the effects of
GC treatment on the migration ability of EPCs toward
the signal of SDF-1. As expected, GC-treated EPCs showed
the low migration ability toward SDF-1 compared to the
untreated cells (Figure 2E). In addition, treatment EPCs with
a CXCR4 antibody, AMD3100, also showed the similar
impaired migration ability, suggesting the direct role of
CXCR4 that regulates the mobility of EPCs (Figure 2E).
Taken together, these results showed that GC impaired wound
healing ability in vitro and the migration ability toward
SDF-1 of EPCs by the downregulation of CXCR4 and
CCL2.
GC Impaired the Wound Healing Ability of
EPCs
We next examined the effects of GC on the wound healing
ability of EPCs by a transplantation study using an in vivo
mouse flap model. The wound healing functions of GC-treated
EPCs were analyzed and compared to those in untreated cells.
We found that the injection of untreated EPCs healed the
wounds of mice with a reduction in the necrotic areas at 7
days after transplantation. In contrast, the wound healing ability
of the GC-treated EPCs was significantly impaired, with some
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FIGURE 1 | Glucocorticoid (GC) treatment impaired the proliferation ability of EPCs. (A) Cell morphology of untreated and GC-treated EPCs from one representative
experiment. (B) Apoptotic cells of untreated and GC-treated EPCs. Cells were stained by Annexin V staining, then analyzed by the FACS analysis. The histograms
were from one representative experiment. (C) Cell surface markers of untreated and GC-treated EPCs analyzed by FACS analysis. The histograms were from one
representative experiment. (D) The growth curve of untreated and GC-treated EPCs from one representative experiment. (E) The proliferation assay of untreated and
GC-treated EPCs examined by Cell counting kit-8. The chart shows the mean data from all experiments. Dexamethasone (100 nM, 24-h treatment) was used as a
GC. Untreated: untreated EPCs, 100 nM Dex: GC-treated EPCs. The data represent the mean ± SD. n = 3, **P < 0.01, *P < 0.05. The scale bar indicates 100µm.
The experiment was repeated triplicate.
necrotic areas remaining, similar to control mice without any cell
transplantation (Figures 3A,B).
Because the GC-treated EPCs showed the impaired expression
of CCL2 which related to the inflammatory cell recruitment
ability (25, 26), we performed a histological analysis of the
wound healing process on the third day after transplantation and
the data revealed that mice transplanted with untreated EPCs
showed an increased recruitment of CD45- and Mac-1 positive
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FIGURE 2 | GCs impaired the in vitro migration ability of EPCs via the downregulation of CXCR4. (A) The in vitro wound healing ability of untreated and GC-treated
EPCs by a scratch assay. The images showed the wound closures from one representative experiment taken under a microscope at 100× magnification.
(Continued)
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FIGURE 2 | (B) Quantification of the wound closure area in a scratch assay of untreated and GC-treated EPCs. The data were displayed as the means from all
experiments. (C) The relative mRNA expression of wound healing genes in untreated and GC-treated EPCs. The chart shows the mean data from all experiments.
(D) The relative protein expression of CXCR4 in untreated and GC-treated EPCs identified by a FACS analysis. The FACS histograms were from one representative
experiment. The chart shows the quantification of relative expression of CXCR4 protein. The data were displayed as the means from all experiments. (E) The transwell
assay of untreated, GC-treated EPCs, and CXCR4 antibody-treated EPCs toward SDF-1. AMD3100 (100 nM, 24-h treatment) was used as the CXCR4 antibody. The
images were the migrated EPCs from one representative experiment taken under a microscope at ×100 magnification. The chart shows the quantification of number
of migrated EPCs. The data were displayed as the means calculated from all experiments. Dexamethasone (100 nM, 24-h treatment) was used as a GC. Untreated:
untreated EPCs, 100 nM: GC-treated EPCs. The data represent the mean ± SD. n = 3, ****P < 0.0001, **P < 0.01, *P < 0.05. The scale bar indicates 100µm. The
experiment was repeated triplicate.
cells to the wound sites compared to mice transplanted with
GC-treated EPCs (Figures 3C,D). In addition, on the seventh
day after transplantation, mice injected with untreated EPCs
showed a greater number of CD31-positive vascular endothelial
cells than mice injected with GC-treated EPCs (Figures 3C,D).
In addition, to examine the effects of GC treatment on the
homing and migration ability of EPCs to the wound sites, we
quantified the PKH-labeled EPCs in the wound regions on the
first day of transplantation. We found that there were fewer
PKH-positive cells at the wound sites of mice transplanted with
GC-treated EPCs than in those injected with untreated EPCs
(Figures 3E,F).
We previously reported the impaired wound healing ability of
EPCs with high activity of ALDH (Alde-high EPCs) due to the
low expression of CXCR4 compared to those with low activity of
ALDH (Alde-low EPCs) (19). In order to clarify the direct role
of CXCR4 in the wound healing ability of EPCs, we blocked the
activity of CXCR4 by its antibody, AMD3100, and compared the
necrotic area in the transplantation study. As expected, similar
to the effects of GC, blocking CXCR4 in EPCs showed the
impaired wound healing function in the flap mice (Figure 3G),
suggesting CXCR4 is responsible for the wound healing ability of
EPCs.
Taken together, these data demonstrated that GCs impaired
the wound healing functions of EPCs.
GC-Impaired Prostaglandin E2 Production
Was Involved in the Downregulation of
CXCR4 in EPCs
Previous studies have shown that GCs are a strong inhibitor
of the arachidonic acid cascade, resulting in less production
of prostaglandin E2 (PGE2) in macrophages, vascular smooth
muscle cells, and MSCs (27–30). In addition, other studies
have suggested that the expression of CXCR4 is elevated in the
presence of PGE2 (31). Therefore, we next investigated whether
or not GC impaired the production of PGE2 to cause the
downregulation of CXCR4 expression in EPCs. Cyclooxygenase
(COX) and prostaglandin dehydrogenase (mPGES) are reported
to be key enzymes in the catabolism of PGE2 (32–34). We
found that GC treatment impaired the expression of COX-2 and
mPGES-1 in EPCs, implying the negative effects of GCs on the
PGE2 production of these cells (Figure 4A).
Next, in order to clarify the involvement of PGE2 in the
downregulation of the CXCR4 expression in GC-treated EPCs,
we examined whether or not treatment with PGE2 could reverse
the expression of CXCR4 of these cells. The data showed that
treatment of PGE2 rescued the GC-impaired mRNA and protein
expression of CXCR4 in EPCs (Figures 4B,C). Furthermore,
consistent with the upregulation of CXCR4 in the presence
of PGE2, the migratory capacity of GC-treated EPCs was also
recovered by PGE2 treatment (Figure 4D). Taken together, these
results suggested that GC downregulated the expression of
CXCR4 in EPCs by the impairment of PGE2 synthesis via COX-2
and mPGES-1.
EP4/AKT Signaling Was Involved in the
GC-Downregulated PGE2 in EPCs
A previous reports showed that PGE2 exerted its activity by
interaction with a G-protein-coupled receptor family (GPCRs)
consisting of EP1, EP2, EP3, and EP4 subtypes, resulting in the
different signal transduction and regulation of the expression of
numerous target genes (35). To identify which PGE2 receptors
are affected by GC, we analyzed the gene expression of these
subtypes in EPCs in the presence of GC. We found that, among
these four receptors, GC treatment only impaired the expression
of EP4 in EPCs. In addition, treatment with PGE2 reversed the
negative effects of GC on the EP4 expression, suggesting that
EP4 is the PGE2 receptor related to the effects of GC on EPCs
(Figure 5A).
The EP2 and EP4 receptors which mediate the increased
cAMP concentrations had been thought to have similar effects
in some biological process; however, recently, their distinct roles
were reported (36, 37). It might be because of the selective
expression of either of them in cells and the selective actions
on the different signaling pathways (37). It is reported that EP4
but not EP2 couples to PI3K which regulates the migration of
dendritic cells in themouse suggesting the role of EP4/PI3K/AKT
in the regulation of migration ability of the cells (37). Therefore,
we next examined the role of PI3K/AKT pathways in the GC-
impaired CXCR4 expression in EPCs. As expected, we found the
impaired phosphorylation of AKT in EPCs in the presence of
GC; this effect was rescued by the adding of PGE2 which showed
by the upregulation of pAKT (Figure 5B). In order to clarify
the role of PGE2/PI3K/AKT pathway in the CXCR4 regulation
of GC-treated EPCs, we analyzed the expression of CXCR4 in
the present of a PI3K inhibitor. The effect of PI3K inhibitor
on the phosphorylation of AKT was confirmed (Figure 5C).
The data showed that treatment with PI3K inhibitor abolished
the rescued effects of PGE2 on the GC-treated EPCs in which
CXCR4 expression was impaired (Figure 5D) indicating that
PGE2 reversed the GC-impaired CXCR4 expression in EPCs via
the activation of PI3K/AKT pathway.
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FIGURE 3 | GCs impaired the wound healing ability of EPCs. (A) Wound healing ability of untreated and GC-treated EPCs in flap mouse model. (B) The necrotic area
of the flap tissues injected with untreated and GC-treated EPCs. (C) Immunohistochemistry of CD45-, MAC-1- (at day 3 post-transplantation), and CD31-positive
(Continued)
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FIGURE 3 | cells (at day 7 post-transplantation) in flap tissues injected with untreated and GC-treated EPCs observing under a microscope at 200× magnification.
(D) Quantification of CD45-, MAC-1- (at day 3 post-transplantation), and CD31-positive cell numbers (at day 7 post-transplantation) in flap tissues injected with
untreated and GC-treated EPCs observing under a microscope at 200× magnification. (E) PKH-positive EPCs in flap tissues injected with untreated and GC-treated
EPCs observing under a microscope at 200× magnification. (F) Quantification of PKH-positive EPCs in flap tissues injected with untreated and GC-treated EPCs
observing under a microscope at 200× magnification. From A–F, the data were calculated from five individual mice from one representative experiment. The data
represent the mean ± SD. n = 5, ***P < 0.001, **P < 0.01, *P < 0.05. (G) Wound healing ability of untreated and CXCR4 antibody-treated EPCs in flap mouse
model. AMD3100 (100 nM, 24-h treatment) was used as a CXCR4 antibody. The data were calculated from three individual mice from one representative experiment.
The data represent the mean ± SD. n = 3, **P < 0.01. Dexamethasone (100 nM, 24-h treatment) was used as a GC. Untreated: untreated EPCs, 100 nM: GC-treated
EPCs. The scale bar indicates 100µm. The experiment was repeated triplicate.
Taken together, these results demonstrated that GC
impaired the EP4/AKT signaling which was involved in the
downregulation of CXCR4 expression of EPCs.
GC Downregulated the Expression of
CXCR4 via the Independent Impairment of
the HIF2α and PGE2 Pathways
We previously reported the HIF2α-dependent upregulation of
CXCR4 in Alde-low EPCs under hypoxic conditions, which
promotes the migration and wound healing function of the
cells (13, 19). To examine whether or not GC causes similar
negative effects that impair the CXCR4 expression in EPCs under
hypoxic conditions, we next analyzed untreated and GC-treated
EPCs under hypoxic conditions. As expected, in the control
EPCs without treatment of GC, we observed the upregulation
of CXCR4 at both the mRNA and protein levels under hypoxic
conditions (Figures 6A,B). However, in the GC-treated EPCs,
the upregulation of CXCR4 under hypoxic conditions was
abrogated (Figures 6A,B). Interestingly, this detrimental effect
of GC on the CXCR4 expression was rescued by treatment
with PGE2 (Figures 6C,D), indicating the similar effects of
GC on EPCs under both normoxic and hypoxic conditions of
downregulating the expression of CXCR4 via the impairment of
the PGE2 pathway.
Our previous report described the functions of the HIF2α
pathway, which plays a key role as an upregulator of the CXCR4
expression in EPCs under hypoxic conditions (19). In order to
examine whether or not the HIF2α pathway is involved in the
GC-impaired reduction of the CXCR4 expression under hypoxic
conditions, we next examined the effects of GC on the expression
of HIF2α. Interestingly, we found that GC also impaired the
expression of HIF2α under hypoxic conditions (Figure 6E).
COX2/PGE2 was reported to upregulate the expression of
HIF2α under hypoxic conditions in hepatocellular carcinoma
cells (38). Therefore, we thought that PGE2might also upregulate
the expression of HIF2α in EPCs under hypoxic conditions. In
order to test this hypothesis, untreated EPCs were cultured in the
presence of PGE2 under hypoxic conditions, and the expression
of HIF2α was examined. Unexpectedly, we found that PGE2
showed no effect on the expression of HIF2α (Figure 6F). This
suggested that the HIF2α and PGE2 pathways independently
regulated the expression of CXCR4 in EPCs under hypoxic
conditions.
Taken together, these results indicated that GC exerted
similar effects on the CXCR4 expression in EPCs under both
normoxic and hypoxic conditions. However, under hypoxic
conditions, the GC-impaired CXCR4 expression in EPCs was
caused independently by the downregulation of the HIF2α or
PGE2 pathway.
DISCUSSION
In the present study, we showed that GC downregulated the
expression of CXCR4, thus abrogating the wound healing
ability of EPCs. GC-treated EPCs showed a poor migration
ability and dysfunction in the recruitment of inflammatory
cells and neovascularization. Of note, the production of
PGE2 was associated with the detrimental effects of GCs on
EPCs. GCs impaired the expression of COX2 and mPGES1,
which are the main enzymes of PGE2 synthesis. Treatment
with PGE2 upregulated the expression of EP4 receptors and
activated the PI3K/AKT signaling pathways, thereby reversing
the impaired effects of GCs on the expression of CXCR4 in EPCs.
Importantly, our data demonstrated that, GCs similarly impaired
the expression of CXCR4 under hypoxic conditions as under
normoxic conditions, as proven by the impairment of PGE2 and
another pathway related to HIF2α. Of note, PGE2 and HIF2α
acted independently in the regulation of CXCR4 in EPCs under
hypoxic conditions (Figure 7, proposed model).
Although no significant influence on the EPCs was observed
under microscopic observation, GC treatment decreased the
proliferation ability of EPCs. GCs are known to exert anti-
proliferative activities against various cells, including neural
cells, osteoblasts, osteosarcoma cells, hepatoma cells, and lung,
ovarian, and prostate cancer cells (39–41). It has been reported
that GC inhibits cell proliferation by arresting the cell cycle
via several molecular mechanisms, including the upregulation
of cyclin-dependent kinase inhibitors (CKIs), such as p21,
that inactivate the cyclinD/Ckd4 complex, leading to G1/G0
arrest (42, 43), or affects other regulators, such as cyclinD1
and c-myc, which induce arrest in the G1 phase (44, 45). In
addition, although in our present study, GC treatment showed
no apoptosis induction in EPCs after 24-h treatment, a further
time-course study is necessary to examine the effects of GC to
induce EPCs apoptosis at later time points.
Additionally to the impaired-proliferation, GC treatment
downregulated the expression of wound healing genes in EPCs,
including CCL2 and CXCR4. CCL2 is the proinflammatory
chemokine which is responsible for the inflammatory cell
recruitment (25). It is reported that CCL2 promotes wound
healing in diabetic mice by inducing macrophage (26). The
downregulation of CCL2 in GC-treated EPCs might be involved
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FIGURE 4 | GC-impaired prostaglandin E2 production was involved in the downregulation of CXCR4 in EPCs. (A) The relative mRNA expression of COX2 and
mPEGS1 in untreated and GC-treated EPCs. (B) The relative mRNA expression of CXCR4 in untreated, GC-treated EPCs, and GC-treated EPCs in the presence of
PGE2. (C) The relative protein expression of CXCR4 in untreated, GC-treated EPCs, and GC-treated EPCs in the presence of PGE2 by a FACS analysis. (D) An
in vitro scratch assay of untreated, GC-treated EPCs, and GC-treated EPCs in the presence of PGE2 observing under a microscope at 100× magnification.
Dexamethasone (100 nM, 24-h treatment) was used as a GC. Untreated: untreated EPCs, 100 nM: GC-treated EPCs, 100 nM + PGE2: GC-treated EPCs in the
presence of PGE2. The data represent the mean ± SD. n = 3, **P < 0.01, *P < 0.05. The scale bar indicates 100µm. The experiment was repeated triplicate. The
charts showed the overall mean data from all experiments.
in the low recruitment of CD45 and Mac1-possitive cells to
the wound sites on the third day after transplantation of GC-
treated EPCs in the mouse model. The SDF-1/CXCR4 cascade
is a major cascade underlying the mobilization of EPCs (46). We
previously reported on the GC-impaired wound healing function
of MSCs by the suppression of SDF-1 (5). In the present study,
although no significant effects on the expression of SDF-1 were
noted, GC still adversely affected the wound healing function of
EPCs via interference with the regulation of CXCR4. CXCR4 is
a G-protein coupled receptor that is highly expressed on EPCs
Frontiers in Medicine | www.frontiersin.org 11 September 2018 | Volume 5 | Article 276
Carolina et al. Dysfunction of EPCs by Glucocorticoid
FIGURE 5 | GCs downregulated CXCR4 via the impaired PGE2/EP4/AKT signaling in EPCs. (A) The relative mRNA expression of EP4 in untreated, GC-treated EPCs,
and GC-treated EPCs in the presence of PGE2. (B) The relative protein expression of pAKT/AKT in untreated, GC-treated EPCs, and GC-treated EPCs in the
presence of PGE2. (C) The inhibition of PI3K/AKT pathway in GC-treated EPCs in the presence of PGE2. LY294002 was used as a PI3K inhibitor. (D) The relative
mRNA expression of CXCR4 in GC-treated EPCs in the presence of PGE2 and PI3K inhibitor. Dexamethasone (100 nM, 24-h treatment) was used as a GC.
Untreated: untreated EPCs, 100 nM: GC-treated EPCs, 100 nM + PGE2: GC-treated EPCs in the presence of PGE2, 100 nM + PGE2 + LY: GC-treated EPCs in the
presence of PGE2 and PI3K inhibitor. LY: LY294002. The data represent the mean ± SD. n = 3, **P < 0.01, *P < 0.05. The experiment was repeated triplicate. The
charts showed the overall mean data from all experiments.
(47). In injured tissues, the surrounding cells secrete SDF-1,
which recruits the CXCR4-expressing cells to the wound sites
and play their functions in wound healing (48). A study in
coronary artery disease patients showed that the dysregulation
of CXCR4 signaling reduced the migratory capacity of EPCs in
these patients compared to healthy subjects (49). In our study, we
found that, under GC treatment, the downregulation of CXCR4,
together with the contribution of impaired proliferation, led to a
reduced in vitro wound healing ability of EPCs in the migration
scratch assay. These impaired effects might be involved in the low
homing ability of EPCs to the injured tissues in the mouse flap
model. These findings suggested the need for further studies on
the CXCR4 regulatory effects and functions of EPCs derived from
patients receiving GC therapy.
The present findings raised questions about how GCs reduce
the CXCR4 expression in EPCs. PGE2 has been proven to induce
the expression of CXCR4 in several cells, such as myeloid-derived
suppressor cells and microvascular endothelial cells (31, 50). In
addition, the inhibitory effects of GCs on prostaglandin synthesis
have been well-demonstrated in various cell types and tissues
by the mediation of multiple pathways (51, 52). Therefore, we
hypothesized that GCs impaired the expression of CXCR4 in
EPCs through activity against prostaglandin synthesis. Indeed,
our data demonstrated that GCs interfered with the production
of PGE2 by the impairment of two enzymes: COX2 andmPGES1.
Of note, treatment with PGE2 rescued the expression of CXCR4
in the GC-treated EPCs, which confirmed our hypothesis.
PGE2 is a potent upstream mediator of several genes through
interaction with its receptors (EPs), including EP1, EP2, EP3, and
EP4, thereby recruiting the transcription factors and modulating
the target gene expression (37). Several reports have described
the role of PGE2-EPs signaling in the SDF-1-CXCR4 chemokine
system (53, 54). EP3 or EP4 knockout suppressed SDF-1 and
CXCR4-positive stromal cells in mice (53). PGE2 promotes the
homing ability of CD34-positive cells through EP2 and EP4 (54).
However, thus far, how GC affects the PGE2 receptors and its
effects on the regulation of CXCR4 in EPCs have been unclear.
We found that GC impaired the expression of EP4 but not EP1,
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FIGURE 6 | GCs downregulated the expression of CXCR4 via the independent impairment of the HIF2α and PGE2 pathways. (A) The relative mRNA expression of
CXCR4 in untreated and GC-treated EPCs under normoxic and hypoxic conditions. (B) The relative protein expression of CXCR4 in untreated and GC-treated EPCs
under normoxic and hypoxic conditions. (C) The relative mRNA expression of CXCR4 in untreated EPCs, GC-treated EPCs, and GC-treated EPCs in the presence of
PGE2 under hypoxic conditions. (D) The relative protein expression of CXCR4 in untreated EPCs, GC-treated EPCs, and GC-treated EPCs in the presence of PGE2
under hypoxic conditions. (E) The expression of HIF2α protein in untreated and GC-treated EPCs under normoxic and hypoxic conditions. (F) The expression of HIF2α
protein in untreated EPCs in the presence of PGE2 under normoxic and hypoxic conditions. Dexamethasone (100 nM, 24-h treatment) was used as a GC. Untreated:
untreated EPCs, 100 nM: GC-treated EPCs, 100 nM + PGE2: GC-treated EPCs in the presence of PGE2, Untreated + PGE2: untreated EPCs in the presence of
PGE2. The data represent the mean ± SD. n = 3, **P < 0.01. The experiment was repeated triplicate. The charts showed the overall mean data from all experiments.
EP2, or EP3 in EPCs which suggested the involvement of EP4
receptor in this pathway. In addition, previous reports showed
that only EP4 regulates the migration of numerous cells (55–57).
For instance, EP4 regulates the migration of dendritic cells in
mice via selective action on PI3K (55). In addition EP4 is also
involved in breast cancer cell migration during tumor invasion
(56) and enhances the migration of rat smooth muscle cells (57).
Hypoxia plays a crucial role in modulating the functions of
many types of cells via the activation of HIF (58). Hypoxic
preconditioning promoted the survival, differentiation, and
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FIGURE 7 | Proposed model: GCs impaired the wound healing functions of EPCs via the impairment of CXCR4 regulated pathways. GCs downregulated the
expression of CXCR4 under both normoxic and hypoxic conditions, thereby reducing the migration and wound healing ability of EPCs. Under normoxic condition,
GCs impaired the expression of COX2/mPEGS1, thereby suppressing the PGE2/EP4/AKT pathway, which downregulated the CXCR4 expression. Under normoxic
conditions, in addition to the PEG2 pathway, GCs independently impaired the HIF2α pathway, consequently decreasing the expression of CXCR4.
function of EPCs for the preservation of the left ventricle
in acute myocardial ischemia mice (59). In addition, hypoxic
treatment upregulated the expression of CXCR4 in EPCs, thereby
enhancing the migration of the cells (60). We therefore expected
that hypoxic treatment might reverse the negative effects of
GCs on the impaired expression of CXCR4. However, our data
showed that GC reduced the expression of CXCR4 in EPCs under
not only normoxic but also hypoxic conditions, although this
impairment was able to be rescued by PGE2. We previously
showed that the CXCR4 expression is directly regulated by
HIF2α under hypoxic conditions in Alde-low EPCs (19). In
our current study, we found that the expression of HIF2α was
also downregulated by GC treatment under hypoxic conditions,
highlighting another CXCR4-regulated pathway impaired by
GC. Previous report described the role of the COX2/PGE2
pathway in the upregulation of HIF2α in carcinoma cells (38);
however, in our present study, PGE2 exerted no significant
effects on the expression of HIF2α in EPCs, suggesting the cell-
specific regulation of HIF2α would exist. In addition, our data
indicated the different mechanisms underlying the regulation
of CXCR4 under normoxic and hypoxic conditions. Under
hypoxic conditions, PGE2 and HIF2α operate as independent
pathways that are impaired by GC, consequently suppressing the
expression of CXCR4 in EPCs.
Under trauma conditions, peripheral tissues—through
myofibroblasts, epithelial cells, and keratinocytes—show an
increased production of EPC-mobilizing factors, like VEGF,
G-CSF, bFGF, PDGF, and most importantly SDF1, as a potent
chemoattractant of EPCs (61). MSCs are considered to contribute
to the vascular niche development by providing growth factors
(62). SDF-1 production by resident MSCs might therefore
encourage the homing ability of EPCs to ischemic sites. A
previous report found that the level of SDF-1 protein in the
serum of GC-treated patients was significantly decreased
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compared with untreated patients (63). Because the biologic
effects of chemokines are mediated by their corresponding
receptors, the interplay between SDF-1 and CXCR4 may provide
another way to regulate the distribution of circulating EPCs
(64). Similar to our previous finding that GCs reduced SDF-1
production in MSCs (5), the present study showed that GCs also
reduced the CXCR4 expression in EPCs. These two discoveries
thoroughly show why GC-treated patients have a reduced
number of circulating EPCs and a consequently impaired
angiogenic ability that leads to dreadful outcomes, like avascular
necrotic femoral head (ANFH).
Synthetic GCs have been developed to help treat many
different conditions, such as autoimmune disorders, allergies and
asthma, cancer, and surgery (24). Despite the multi-functions,
GCs causes various side effects including chronic wound (65). It
is reported that patients who receive GC treatment for 30 days
prior to wounding or operation have a 2-fold increase in wound
infection, three times increase in wound dehiscence, and four
times increased mortality compared to those who not get the GC
treatment (66). In addition, rheumatoid arthritis patients who
receive long term GC treatment and surgery have the high risk
of delayed wound healing (67). Therefore, it can be implied that
the patients with GC-induced chronic wound have become the
target of EPC therapy which helps to accelerate wound healing.
Our study indicated the negative influences of GC on the wound
healing ability of EPCs by the impairment of PGE2/CXCR4,
which suggested a strategy to improve the function of EPCs. As
autologous cell sources are preferred, the intervention of PGE2 or
CXCR4 to improve wound healing ability of GC-treated patients-
derived EPCs might be useful before the application to clinical
settings.
Previous studies showed that glucocorticoid treatment
impairs the corneal neovascularization in mice and rabbit which
implied the possibility of abnormal vascularization process,
including the dysfunction of EPCs and ECs (68, 69). In addition,
EPCs frommice with aldosterone treatment showed the impaired
differentiation ability to ECs and migration ability. These studies
suggested the in vivo negative effects of GCs on EPCs functions
(70). However, up to now, the influences of GCs on wound
healing ability of EPCs have not yet reported. Therefore, our
present study focused on the effects of in vitro treated GC on
EPCs to provide an idea of how GCs influence EPCs wound
healing functions. Further studies related to in vivo effects of
GCs on EPCs using GC-induced mouse model and GC-treated
patients derived EPCs are required to clarify the regulatory ability
of GCs on EPCs.
In summary, our study demonstrated that GCs suppress
the migration ability and wound healing function of EPCs
by the downregulation of CXCR4 under both normoxic and
hypoxic conditions. Under normoxic conditions, the impairment
of prostaglandin synthases COX2 and mPEGS1 and the
prostaglandin receptor EP4 are involved in the detrimental
effects on GCs on EPCs. Treatment with PGE2 upregulated the
expression of EP4 and consequently activated the PI3K/AKT
pathway, which might be involved in rescuing the GC-impaired
CXCR4 expression in EPCs. Under hypoxic conditions, in
addition to impairment of the PGE2 pathway, GCs exerted
similarly detrimental effects on the HIF2α pathway that
independently downregulated the expression of CXCR4 in EPCs.
Further studies should be performed to carefully assess wound
healing functions of EPCs derived from patients who have been
receiving long-term treatment with GCs.
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